Lasa Supergenerics Share Price Today | Stock Price & Lasa Supergenerics Share Screener
As of September 8, 2026, the live Lasa Supergenerics share price (NSE: LASA) is ₹6.69 on NSE and ₹5.67 on BSE, up 0.15% from the previous close, with shares trading between ₹6.65 and ₹6.83 in today's trading session, and a 52-week range of ₹5.67–₹12.04. Check LASA 52-week high low for the annual price range and momentum. Use the Lasa Supergenerics stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Lasa Supergenerics opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹7 and net income of ₹-17, with EBITDA of ₹-9, an operating margin of 417.0% and a profit margin of -242.9%.
Lasa Supergenerics Share Price Chart
Track the current stock price of Lasa Supergenerics with an interactive chart. Analyse LASA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Lasa Supergenerics stock quote in one place.
The quote of ₹6.69 sits between the 52-week low of ₹5.67 and the 52-week high of ₹12.04, and the latest session moved 0.15% from the previous close.
Lasa Supergenerics Company Profile - Fundamental Screener
Screen Lasa Supergenerics company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LASA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE670X01014.
Company Details
Classification
Identifiers and Leadership
Lasa Supergenerics Balance Sheet Screener
Screen LASA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹102, down from ₹151 in 2024.
Latest statistics put total assets at ₹102 and shareholder funds at ₹84, with a leverage ratio of 0.13.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 102 | 151 | 164 | 209 | 208 | 232 | 259 | 287 | 228 | 0 |
| Current Assets | 33 | 38 | 39 | 66 | 64 | 76 | 86 | 109 | 79 | 0 |
| Fixed Assets | 68 | 110 | 119 | 137 | 143 | 152 | 162 | 170 | 119 | 0 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 1 | 5 | 3 | 7 | 8 | 15 | 46 | 62 | 83 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 84 | 97 | 118 | 158 | 159 | 142 | 105 | 117 | 76 | 0 |
| Share Capital | 50 | 50 | 50 | 50 | 41 | 41 | 23 | 23 | 0 | 0 |
| Reserves & Surplus | 32 | 47 | 68 | 108 | 118 | 101 | 82 | 95 | 75 | 0 |
Lasa Supergenerics Income Statement Screener - Profit & Revenue Analysis
Screen Lasa Supergenerics income statement and profit fundamentals. Analyze LASA quarterly results. Lasa Supergenerics reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹7 and net profit was ₹-17, equal to earnings per unit of ₹-3.30, at an operating margin of 417%.
In that period expenses were ₹16, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹25 and net profit of ₹-35.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||
| Revenue | 7 | 25 | 148 | 104 | 131 | 137 | 202 | 168 | 170 | 247 | 201 | 0 |
| Expenses | 16 | 54 | 136 | 102 | 136 | 121 | 155 | 137 | 159 | 202 | 153 | 0 |
Operating Costs and Margins | ||||||||||||
| EBITDA | -9 | -28 | 11 | 2 | -5 | 16 | 47 | 30 | 12 | 45 | 48 | 0 |
| Operating Profit % | 417.00% | -113.00% | 4.00% | 2.00% | -5.00% | 12.00% | 23.00% | 18.00% | 7.00% | 17.00% | 23.00% | 0.00% |
| Depreciation | 6 | 6 | 12 | 11 | 13 | 15 | 16 | 17 | 19 | 18 | 8 | 0 |
| Interest | 0 | 0 | 3 | 2 | 4 | 0 | 2 | 8 | 8 | 11 | 12 | 0 |
Profit and Earnings | ||||||||||||
| Profit Before Tax | -16 | -35 | -19 | -19 | -42 | -6 | 30 | 5 | -16 | 15 | 2 | 0 |
| Tax | 0 | 0 | -5 | 3 | -4 | -1 | 7 | 1 | -4 | 3 | 0 | 0 |
| Net Profit | -17 | -35 | -15 | -22 | -39 | -5 | 23 | 4 | -12 | 12 | 2 | 0 |
| EPS | -3.30 | -6.80 | -2.95 | -4.34 | -7.71 | -1.06 | 5.60 | 0.89 | -5.26 | 5.43 | 1.15 | 0.00 |
Lasa Supergenerics Cash Flow Screener - Liquidity Fundamentals
Screen LASA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹3.
Over the same period, investing activities provided ₹8 and financing activities used ₹6.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -3 | 2 | -17 | 9 | 41 | 14 | 41 | 40 | -3 | 0 |
| Investing Activities | 8 | 0 | 11 | -3 | -4 | -2 | -7 | -44 | 0 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | -6 | -2 | -4 | 0 | -36 | -10 | -33 | 4 | 0 | 0 |
| Net Cash Flow | 0 | 0 | -10 | 6 | 1 | 2 | 0 | 0 | -3 | 0 |
Lasa Supergenerics Shareholding Pattern Screener
See Lasa Supergenerics shareholding pattern with promoter, FII, and DII holdings. Check Lasa Supergenerics promoter holding and ownership changes for LASA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 53.65%, foreign institutions 0.00%, domestic institutions 0.00% and the public 42.04%, spread across 27,702 shareholders.
The shareholder count was 27,702 in 2026-Mar, compared with 27,188 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.12% | 0.00% | 0.01% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 42.04% | 34.08% | 34.08% | 42.14% | 42.04% | 34.15% | 34.24% | 34.08% |
| Other Holding | 4.31% | 12.27% | 12.27% | 4.21% | 4.31% | 12.08% | 12.11% | 12.26% |
| Shareholder Count | 27,702 | 27,188 | 27,188 | 28,656 | 28,120 | 27,615 | 27,217 | 27,969 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Lasa Supergenerics. Lasa Supergenerics dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.25 | 1.38% |
| 2021-March | ₹0.25 | 0.60% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Lasa Supergenerics Stock Index Membership - Nifty & Sensex
See which indices include Lasa Supergenerics stock. Check LASA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Lasa Supergenerics Market Events Screener - Corporate Actions
Get Lasa Supergenerics corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Lasa Supergenerics stock events that may affect LASA share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated August 14, 2026 and Quarterly Result Announcement dated May 29, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -1.79% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 6.27% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 5.05% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -5.63% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -6.51% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | 32.84% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 1.95% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | -12.30% |
| 2025-02-22 | 2025-02-22 | Extraordinary General Meeting | NA | -7.24% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -4.53% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.89% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | -2.28% |
| 2022-09-16 | 2022-09-19 | Dividend | ₹ 0.25 /share | -32.02% |
| 2021-09-15 | 2021-09-17 | Dividend | ₹ 0.25 /share | -6.54% |
Lasa Supergenerics Competitors Screener - Peer Stocks Comparison
Screen LASA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 440,278 | 36.48 | 61,674 | 12.69% | 11,565 | 33.19 |
| Divis Laboratories | 244,178 | 84.64 | 11,067 | 13.95% | 2,568 | 59.21 |
| Torrent Pharmaceuticals | 184,478 | 87.77 | 13,886 | 20.34% | 2,138 | 44.26 |
| Zydus Life Science | 110,585 | 24.32 | 27,658 | 17.64% | 5,026 | 41.59 |
| Cipla | 109,140 | 32.86 | 29,045 | 2.24% | 3,870 | 32.08 |
| Laurus Labs | 104,025 | 97.64 | 6,868 | 22.01% | 890 | 60.27 |
| Dr Reddys Laboratories | 95,570 | 30.44 | 35,059 | 3.90% | 4,158 | 41.23 |
| Aurobindo Pharma | 95,513 | 25.98 | 34,145 | 5.56% | 3,503 | 53.00 |
| Lupin | 94,336 | 17.27 | 29,039 | 26.75% | 5,356 | 24.64 |
| Mankind Pharma | 94,184 | 45.49 | 14,636 | 14.85% | 1,938 | 37.66 |
Lasa Supergenerics Company Announcements - News & Reports Screener
Screen LASA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated September 30, 2026.
The next most recent announcements are dated September 30, 2026 and August 26, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-09-30 | Notice Of The Annual General Meeting | - |
| 2026-09-30 | Board Meeting Outcome for Outcome Of The Baord Meeting | - |
| 2026-08-26 | Board Meeting Outcome for Appointment Of Mr Janardan Savala As On 26-08-2026 Additional Director In The Capacity Of Executive Director | - |
| 2026-08-25 | Announcement under Regulation 30 (LODR)-Cessation | - |
| 2026-08-14 | Integrated Filing For Quarter Ended June 30 2026 | - |
| 2026-08-14 | Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended June 30 2026 | - |
| 2026-08-04 | Board Meeting Intimation for The Quarter Ended June 302026 | - |
| 2026-06-29 | Closure of Trading Window | - |
| 2026-05-30 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Integrated Filing As On March 31 2026 | - |
| 2026-05-29 | Related Party Transaction As On 31St March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Revised Outcome Of Board Meeting For Quarter Ended 31 March 2026 | - |
| 2026-05-29 | Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended March 31 St 2026 | - |
| 2026-05-19 | Board Meeting Intimation for Quarter And Year Ended March 31St 2026 | - |
| 2026-05-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-16 | Declaration With Respect To Non -Applicability Of Large Entities | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-02-13 | Integrated Filing For Quarter Ended December 31 2025 | - |
| 2026-02-13 | Results For Quarter Ended 31St December 2025 | - |
| 2026-02-13 | Board Meeting Outcome for Outcome Of Board Meeting For Quarter Ended 31St December 2025 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹6.69, within a 52-week range of ₹5.67 to ₹12.04. The P/E ratio is -2.00 and the P/B ratio is 0.67, with earnings per unit of ₹-6.80. Market capitalisation stands at ₹31.06 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 12 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.